DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ks3rlb/proteasome) has announced the addition of the "Proteasome Inhibitors Market" report to their offering.
The market for proteasome inhibitors is experiencing rapid transformation. Amgen's acquisition of Onyx Pharmaceuticals, developer of Kyprolis, for $10.4 billion comes just five years after Takeda paid $8.8 billion for Millennium Pharmaceuticals, developer of Velcade, the first in class.
Growing evidence from translational research coupled with evidence from both clinical trials and outcome research have established the proteasome as a novel and legitimate therapeutic target and enabled the rapid development of a second-generation orally available proteasome inhibitors.
Proteasome Inhibitors Market report analyzes both the technology and current market landscape and evaluates both approved and in-development second generation proteasome inhibitor molecules with emphasis on Bortezomib, Carfilzomib, Oprozomib, Ixazomib, Marizomib and Delanzomib.
Proteasome Inhibitors Market report examines Amgen's acquisition of Onyx and Takeda's acquisition of Millennium and volunteers a forecast to 2020.
Key Topics Covered:
1. Hematological Cancer Therapies Market
2. Proteasome Inhibitors
2.1 Velcade (bortezomib)
2.2 Krypolis (carfilzomib)
3. Proteasome Inhibitors Market
4. Second Generation Proteasome Inhibitors
5. Proteasome Inhibitors Market Forecast
Table & Figures
- Johnson & Johnson
For more information visit http://www.researchandmarkets.com/research/ks3rlb/proteasome
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.